Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe Needs More Patient Capital To Nurture Biotechs

Executive Summary

Analysis by the European Investment Bank predicts that EU biotechs face a funding shortfall of up to €40bn by 2021. Barbara Freischem, executive director of European Biopharmaceutical Enterprises, who moderated a panel on the topic at BIO-Europe Spring 2018, talked to Scrip about initiatives that could alleviate the shortfall.

Advertisement

Related Content

MIFID II May Hit Small & Midcap EU Biotech Investment
Quality UK Biotechs Will Dodge Post-Brexit VC Drought

Topics

Advertisement
UsernamePublicRestriction

Register

SC100606

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel